styramate

Styramate is a centrally acting skeletal muscle relaxant and anticonvulsant drug. It was developed by Armour Pharmaceutical Company in 1952 and has been marketed under several brand names including Sinaxar and Sinaxamol[1][3][8]. Styramate is notable for producing muscle relaxation without significant sedative effects at therapeutic doses[1][5]. Its mechanism of action involves interruption of nerve transmission in the spinal cord and brain stem rather than direct neuromuscular blockade[3][4]. Animal studies indicate it selectively antagonizes tonic spasms induced by electroshock or convulsants. Clinically, it has been used to treat neurologic and neuromuscular disorders with secondary muscular spasms[3]. The exact molecular mechanism remains unclear but may involve modulation of neurotransmitter release or ion channels related to muscle contraction[6].

Brand names

SinaxarSinaxamolLinaxarMyospaz

Other names

2-hydroxy-2-phenylethyl carbamate